HBOT is not a proven treatment for any autoimmune disease. A Cochrane review of 9 randomized trials found no effect on multiple sclerosis disability progression, and evidence for lupus and rheumatoid arthritis is limited to small studies and animal models. The strongest signals are for autoimmune-related tissue healing, such as refractory inflammatory bowel disease and skin ulcers, where HBOT supports repair rather than changing disease activity. Here is the honest, condition-by-condition picture.
How Does HBOT Affect the Immune System?
HBOT does not simply suppress or boost immunity. At therapeutic pressures it modulates the immune response in two directions at once, which is exactly why its role in autoimmune disease is uncertain.
It suppresses NF-kB, a transcription factor that drives inflammatory gene expression, reducing pro-inflammatory cytokines including TNF-alpha, IL-1, and IL-6. These are the same cytokines targeted by many biologic autoimmune drugs. In collagen-induced arthritis and NOD-mouse models, HBOT increased regulatory T cell frequencies and reduced Th17 cells (Mei et al., Frontiers in Immunology, 2026).1 At the same time, HBOT enhances oxidative killing in neutrophils and macrophages, supporting defense against actual pathogens. That dual nature is covered further in our guide to HBOT and the immune system.
HBOT Evidence by Autoimmune Condition
| Condition | Best available evidence | Verdict |
|---|---|---|
| Multiple sclerosis | Cochrane review, 9 RCTs (Bennett & Heard 2004) | No disease-modifying effect |
| Rheumatoid arthritis | Small studies, case reports | Not standard of care |
| Inflammatory bowel disease | Systematic review (Dulai 2014) | Adjunct in refractory cases |
| Lupus (SLE) | Animal model only (Chen 2003) | Insufficient evidence |
| Fibromyalgia | Randomized trial (Efrati 2015) | Symptom improvement |
Can HBOT Help Multiple Sclerosis?
MS has more HBOT research than any other autoimmune condition, dating to a 1983 New England Journal of Medicine paper that reported improvements in disability. Later research did not hold up. A Cochrane review of nine randomized trials by Bennett and Heard concluded there was no significant effect of HBOT on MS progression or disability.4 Some individual studies and patient reports note improvements in bladder function, fatigue, and quality of life.
Many MS patients in the UK access mild-pressure chambers through MS therapy centers and report subjective symptom relief. The gap between patient experience and trial outcomes may reflect that HBOT eases specific symptoms (fatigue, bladder) without altering the disease course, which is what the trials measured. HBOT is not recommended by mainstream neurology guidelines as a disease-modifying therapy for MS. Our dedicated guide covers HBOT for multiple sclerosis in more depth.
Does HBOT Work for Rheumatoid Arthritis?
HBOT’s anti-inflammatory effects are theoretically relevant to rheumatoid arthritis, where synovial inflammation drives joint destruction. Small studies and case reports have documented reductions in joint pain and inflammatory markers after HBOT, but there are no adequately powered clinical trials. Given the effectiveness of modern biologics, HBOT is not standard of care and is unlikely to replace them. Any role would be as an adjunct for patients with inadequate response to medication, and that remains speculative.
Is HBOT Useful for Inflammatory Bowel Disease?
Some of the more interesting autoimmune data involves IBD. HBOT has been used as an adjunct for refractory Crohn’s fistulas and severe ulcerative colitis. A 2014 systematic review by Dulai and colleagues found that across mostly small studies, a high proportion of refractory Crohn’s disease and ulcerative colitis patients showed clinical improvement with HBOT, though the evidence base was limited and uncontrolled.6 The anti-inflammatory mechanism and support for bowel-wall wound healing make it biologically plausible. It is not standard of care but is sometimes used in refractory or complicated cases at centers with hyperbaric facilities.
What About Lupus and Fibromyalgia?
Systemic lupus erythematosus involves widespread organ damage and a highly variable course. HBOT research in lupus is confined to animal work: Chen and colleagues found that early HBOT attenuated disease severity in lupus-prone mice, with no human clinical data available.3 There is insufficient evidence to recommend HBOT for lupus, though patients with lupus-related complications such as avascular necrosis or non-healing wounds might qualify under other approved indications.
Fibromyalgia is sometimes grouped with autoimmune or inflammatory conditions, though its mechanisms are disputed. It has been studied more rigorously than most: a 2015 randomized controlled trial by Efrati and colleagues reported significant improvements in pain and quality of life after HBOT, with changes in brain activity on SPECT imaging.5 Our HBOT for fibromyalgia article covers that trial in detail.
Inflammatory Versus Autoimmune: An Important Distinction
Not everything marketed as autoimmune shares the same mechanism, and HBOT’s relevance varies accordingly. True autoimmune conditions (lupus, RA, MS) involve a misdirected immune attack on self tissue. Conditions like fibromyalgia and some chronic-pain or gut disorders involve dysregulated inflammation without a clear autoimmune target. HBOT’s anti-inflammatory properties may touch both, but the benefit is more plausible for dysregulated inflammation than for classic autoimmune disease, where targeted disease-modifying therapies dominate. This is one of several chronic conditions where observational interest outpaces controlled evidence.
What Does a Reasonable Approach Look Like?
For serious autoimmune conditions, disease-modifying therapies have proven efficacy in preventing organ damage and slowing disability. HBOT should never replace them. If you and your specialist decide to try it as an adjunct, keep standard treatment in place, set objective baselines (CRP, ESR, DAS28 for RA, SLEDAI for lupus), and run a defined trial course of 20 to 40 sessions with formal assessment before committing to more. Open-ended, expensive off-label treatment without an objective response is not a sound plan for any chronic condition. Our session guide and the side effects and contraindications guide will help you plan around your specific medications.
Frequently Asked Questions
Can HBOT put autoimmune disease into remission?
There is no clinical evidence that HBOT induces remission in any autoimmune disease. It may reduce inflammation and improve some symptoms, but it does not address the underlying immunological dysfunction that drives autoimmune conditions. The Cochrane review of nine MS trials found no effect on disease progression (Bennett and Heard, 2004).
Is HBOT safe while on immunosuppressant medications?
Most immunosuppressants do not directly interact with HBOT, but some medications require review. Certain chemotherapy agents used in autoimmune conditions, such as bleomycin and doxorubicin, have known interactions with high-oxygen environments. Your hyperbaric physician should review your full medication list before treatment begins.
How many HBOT sessions would be needed for autoimmune conditions?
There are no established protocols. Most small studies have used 20 to 40 sessions. A defined trial course with formal symptom and lab assessment before and after is the most reasonable way to judge individual response, rather than open-ended continuation.
Will my rheumatologist support me doing HBOT?
This varies. Some specialists are open to adjunctive approaches when standard treatment is already in place; others are skeptical given the limited evidence. Bringing published research to the conversation and framing HBOT as adjunctive rather than a replacement tends to land better than presenting it as a standalone treatment.
Sources
- Mei S, Wang J, Chen Y, et al. Hyperbaric oxygen therapy modulates immune effector responses and reshapes peripheral immune tolerance: a narrative review. Frontiers in Immunology. 2026. DOI: 10.3389/fimmu.2026.1777972.
- Fang J, Zhang Y, Li X, et al. Clinical efficacy and mechanisms of hyperbaric oxygen therapy in the treatment of rheumatic and immune diseases. Frontiers in Medicine. 2025. DOI: 10.3389/fmed.2025.1706637.
- Chen SY, Chao CM, Chen MF, et al. Early hyperbaric oxygen therapy attenuates disease severity in lupus-prone autoimmune (NZB x NZW) F1 mice. Clinical Immunology. 2003;108(2):103-110. DOI: 10.1016/S1521-6616(03)00091-3.
- Bennett M, Heard R. Hyperbaric oxygen therapy for multiple sclerosis. Cochrane Database of Systematic Reviews. 2004;(1):CD003057. DOI: 10.1002/14651858.CD003057.pub2. PMID: 14974004.
- Efrati S, Golan H, Bechor Y, et al. Hyperbaric oxygen therapy can diminish fibromyalgia syndrome: prospective clinical trial. PLoS ONE. 2015;10(5):e0127012. DOI: 10.1371/journal.pone.0127012. PMID: 26010952.
- Dulai PS, Gleeson MW, Taylor D, et al. Systematic review: the safety and efficacy of hyperbaric oxygen therapy for inflammatory bowel disease. Alimentary Pharmacology & Therapeutics. 2014;39(11):1266-1275. DOI: 10.1111/apt.12753. PMID: 24738651.
- Undersea and Hyperbaric Medical Society. Indications for hyperbaric oxygen therapy. UHMS.
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
